Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cancer Vaccines Headed For Mainstream

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

No longer the odd cousins of traditional pharmaceutical applications, a host of therapeutic cancer vaccines is working through late-stage trials with real, life-extending data already reported and the potential to create a lot of action in the oncology sector.

You may also be interested in...



Top Oncology Partnering Opportunities: Immunotherapy In Vogue

Every November at Elsevier Business Intelligence’s Therapeutic Area Partnerships meeting in Boston, expert consultants present their pick of the top unpartnered oncology candidates. This year NewLink Genetics, Genelux, and Verastem are among those that made the grade.

FDA Advisory Panel To Discuss Vaccines Made From Human Tumor Cell Lines

The Sept. 19 meeting of FDA’s Vaccines and Related Biological Products Advisory Committee comes as several whole-cell cancer vaccines are in Phase III trials.

MedImmune Pipeline Primed To Produce

MedImmune, the biologics arm of performance-challenged AstraZeneca, is poised to lead the parent company into more prosperous times, with positive signals coming from Phase II trials in oncology and asthma and a stake in cancer immunotherapies.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS005087

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel